CHICAGO, Sept. 14, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BMY, CLF, HTZ, …
Pharmaceutical stocks were in the limelight this week with Merck's MRK CEO Ken Frazier resigning from President Donald Trump’s manufacturing council. The sector was also in the news with an investigation being launched into the …
The stock price continued to fall on the next trading day, declining another $2.98 per share, or 4.7%, on unusually heavy …
Analysts have increased the stock’s price target based on the company’s big year in clinical trial results. Bristol Myers Squibb shares were mostly flat during premarket trading Wednesday. The stock has increased 1.5% in the past year. …
The third-quarter earnings season is off to a strong start. The results of the companies that have reported numbers show that earnings and revenue growth pace is accelerating from the first two quarters. In particular, revenue growth has …
StockMarketWire.com - Jill Jones, Non Executive Director, bought 2,800 shares in the company on the 19th July 2017 at a price of 177.64p. The Director now holds 2,800 shares representing 0.00% of the shares in issue.
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Bristol-Myers Squibb Company (“Bristol …
Major pharma companies like Eli Lilly LLY, Bristol-Myers Squibb BMY, GlaxoSmithKline plc GSK and Novartis (Read more: Novartis Q3 Earnings & Sales Top on New Drugs Strength) reported third quarter results this week. While it was …
Bristol-Myers shares have increased almost 4 percent since the beginning of the year, while the Standard & Poor's 500 index has risen slightly more than 3 percent. The stock has climbed 25 percent in the last 12 months. This story was …
Yahoo!4mon